EU to tighten medical controls after breast implant scandal

A breast implant scandal affecting thousands of women this year damaged confidence and highlighted the need to tighten controls in Europe on everyday medical devices, the European Commission said Wednesday.

"We must do our best never to let this happen again," said EU Health and Consumer Policy Commissioner John Dalli, outlining plans for more transparent regulations "better adapted to scientific and ."

The new rules will cover every device, from the simplest plasters to life-support systems by way of in vitro diagnostic instruments, to ensure that they are correctly approved and then monitored in use.

Earlier this year, the French government recommended that faulty breast implants which were prone to rupture made by Poly Implant Prothese (PIP) should be removed.

More than 400,000 women around the world are believed to have received and many countries followed the French lead after the company was found to have used substandard, industrial-grade .

"Everybody was shocked by the scandal ... (which) damaged the confidence of patients, consumers and in the safety of the devices on which they rely every day," Dalli said.

Asked whether his regulations would have prevented the PIP scandal, he said they would "militate against such fraud" but the key issue was that once they were sold there had been no follow up to check the implants.

"What we want to emphasise is" the control of products once they are in use to check that they are made to the specifications laid down and approved, he said.

"If this had happened, the PIP would have been detected many, many years before."

The proposals mean medical devices will now have to undergo a "thorough assessment of safety and performance before they can be sold on the European market," with "control processes ... radically reinforced," a statement said.

The aim is to give healthcare professionals better information on the benefits and risks while manufacturers will benefit from clearer rules, with those not complying excluded from the market.

The market in the 27 EU states plus Norway and Switzerland was worth 95 billion euros in 2009, the statement said.

The proposals now go to the European Council and the European Parliament for approval.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Hormonal therapy for transsexualism safe and effective

Jun 18, 2013

Hormonal therapy for transsexual patients is safe and effective, a multicenter European study indicates. The results will be presented Saturday at The Endocrine Society's 95th Annual Meeting in San Francisco.

Royalty Pharma lets Elan takeover bid expire

Jun 18, 2013

Royalty Pharma has let its latest takeover bid for Irish drugmaker Elan lapse as it decided against pressing ahead with a court challenge of a requirement that it withdraw the offer.

FDA approves new silicone breast implants

Jun 17, 2013

(HealthDay)—MemoryShape breast implants have been approved by the U.S. Food and Drug Administration for breast augmentation in women 22 and older, and for breast reconstruction, the FDA said Friday.

User comments

More news stories

Validating maps of the brain's resting state

Kick back and shut your eyes. Now stop thinking. You have just put your brain into what neuroscientists call its resting state. What the brain is doing when an individual is not focused on the outside world ...

Antioxidant shows promise in Parkinson's disease

Diapocynin, a synthetic molecule derived from a naturally occurring compound (apocynin), has been found to protect neurobehavioral function in mice with Parkinson's Disease symptoms by preventing deficits in motor coordination.

No danger of cancer through gene therapy virus

In fall 2012, the European Medicines Agency (EMA) approved the modified adeno-associated virus AAV-LPL S447X as the first ever gene therapy for clinical use in the Western world. uniQure, a Dutch biotech company, had developed ...